Ms Jessica Broadbent

Biography/ Background

Jessica Broadbent is a University of Adelaide researcher with a background in Clinical Pharmacology (B.Sc. Hons) and Public Health (GDPH). Her early career experience was grounded in conducting and managing Phase I-III clinical drug trials at the University of South Australia School of Pharmacy between 1995 and 2001, during which her interest in disease prevention and epidemiology developed and led to further studies in Public Health.

She joined the Discipline of General Practice in 2003 as the Primary Health Care, Research Evaluation and Development (PHC RED) co-ordinator which has led to her current research role exploring primary health care issues such as depression and help seeking pathways, respiratory disease and antibiotic use for acute bronchitis and, more recently, cardiovascular disease prevention and health literacy.

Jessica holds a concurrent position at the Discipline of Obstetrics and Gynaecology (since 2002) where she has worked as Editorial Assistant for Climacteric: The Journal of the International Menopause Society (until 2005) while undertaking research in women’s health and hormone therapy use. More recently she is involved in exploring the role of genetic mutations in cerebral palsy causation as a member of the South Australian Cerebral Palsy Research Group (SACPRG).

Qualifications

Graduate Diploma in Public Health, The University of Adelaide (2006) 

Bachelor of Science (Honours) - Pharmacology, The University of Adelaide, Department of Clinical and Experimental Pharmacology. Thesis entitled: ‘Investigations into the potential anticancer properties of the soybean isoflavone genistein’ (1994)  

Bachelor of Science, The University of Adelaide (1990-1993) 

Research Interests

• Cardiovascular disease, risk factors, risk perception and family history
• Health literacy
• Respiratory health, acute bronchitis and antibiotic use
• Mental health, depression and help seeking pathways
• Health service utilisation in general practice
• Women's health, contraception and hormone therapy use
• Cerebral palsy, genetic factors associated with causation

Current Research

• Awareness, perception and knowledge of cardiovascular disease risk and prevention among residents in the north west districts of Adelaide (Funding: Northern Communities Health Foundation)
• Opportunistic screening for cardiovascular disease risk factors in general practice (Funding: Northern Communities Health Foundation)
• Increasing cardiovascular risk assessment in first degree relatives of patients with premature IHD: a RCT (Funding: NHMRC)
• A genomic basis for cerebral palsy - studies on a large Australian cohort (Funding: NHMRC), and other sub-studies associated with this larger project
• Multi-center, open-label, uncontrolled study to investigate the efficacy and safety of the transdermal contraceptive patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene (material no. 80876395) in a 21-day regimen for 13 cycles in 1,650 healthy female subjects (Sponsored Trial: Bayer Healthcare)

Publications

O'Callaghan M, MacLennan A, Gibson C, McMichael G, Haan E, Broadbent J, Priest K, Goldwater P,  Dekker G (2010). The Australian Cerebral Palsy Research Study Protocol for a national collaborative study investigating genomic and clinical associations with cerebral palsy. Journal of Paediatrics & Child Health (in press).

MacLennan AH, Gill TK, Broadbent JL and Taylor AW (2009). Continuing decline in hormone therapy use: population trends over 17 years. Climacteric, 12: 122–130.

Gupta R, Stocks N and Broadbent J (2009). Cardiovascular risk assessment in Australian General Practice. Australian Family Physician, 38 (5): 364-368.

Fuller J and Broadbent J (2006). Mental health referral role of rural financial counsellors. Australian Journal of Rural Health, 14 (2): 79–85.

MacLennan AH, Broadbent JL, Lester S, Moore V (2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2001;(1):CD002978.

Record IR, Broadbent JL, King RA, Dreosti IE, Head RH and Tonkin AL (1997). Genistein inhibits growth of B16 melanoma cells in vivo and in vitro and promotes differentiation in vitro. International Journal of Cancer, 72: 860-864.

King RA, Broadbent JL and Head RJ (1996). Absorption and excretion of the soy isoflavone Genistein in rats. Journal of Nutrition, 126 (1): 176-182.

Conference Presentations

Broadbent J, Stocks N, Taylor A, Grant J, Adams R & Seidel B (2009). Awareness, perception and knowledge of cardiovascular disease in the north western districts of Adelaide. PHCRED Tri-State Conference, Alice Springs. Research presentation.

Broadbent J, Stocks N, Crockett A, Turnidge J, Veale A & Paine B (2007). Acute bronchitis in general practice: what presenting factors predict poor outcome? GP & PHC Research Conference, Sydney. Research Presentation & Conference Abstract: 2007, Paper Sessions, Quality of care.

Fuller J & Broadbent J (2005). A survey of Australian rural financial counsellors—first points of contact in primary mental health care. GP & PHC Research Conference, Adelaide. Conference Abstract: 2005, Paper presentation, Mental Health.

Cabot JL, Broadbent JL, Nation RL, Evans AM, Shanahan KM & Hsyu P-H (1996). Influence of ranitidine on the renal clearance of triamterene in the rat isolated perfused kidney. APSA Meeting, December 1995, Adelaide. Abstract publications details: Australian Journal of Hospital Pharmacy 26, 606-607.

Broadbent J, Dreosti I, Record I & Tonkin AL (1994). An inhibitory role of genistein on the growth characteristics of B16 melanoma cells and BalbC 3T3 fibroblast in vitro. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologist Meeting December 1994, Auckland NZ. Proceedings of ASCEPT, Volume 1 December.

 

 

 

Entry last updated: Friday, 14 Sep 2012